Comparative Pharmacology
Head-to-head clinical analysis: SERENTIL versus SPARINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SERENTIL versus SPARINE.
SERENTIL vs SPARINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
SERENTIL (mesoridazine) is a phenothiazine antipsychotic that blocks postsynaptic dopamine D2 receptors in the mesolimbic system, and also exhibits alpha-adrenergic blocking, anticholinergic, and antihistaminic effects. It has high affinity for D2, 5-HT2A, and alpha-1 receptors.
Phenothiazine antipsychotic; blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors; also blocks alpha-adrenergic receptors, and has anticholinergic and antihistaminergic effects.
Oral: 50–100 mg 3 times daily; maximum 400 mg/day. IM: 25 mg every 4–6 hours.
Promazine hydrochloride: 25-50 mg intramuscularly or intravenously every 4-6 hours as needed; maximum 300 mg/day. Alternatively, oral: 25-200 mg every 4-6 hours; maximum 1000 mg/day. Route and frequency depend on indication and patient response.
None Documented
None Documented
Terminal elimination half-life is approximately 24-30 hours in adults. Does not correlate well with duration of antipsychotic effect due to active metabolite formation.
Terminal elimination half-life: 10-20 hours; clinical context: allows once or twice daily dosing; extended in elderly and hepatic impairment
Primarily renal (70-80% as conjugated and unconjugated metabolites) and fecal (15-20%). Biliary excretion contributes to enterohepatic circulation.
Primarily renal (70-80% as metabolites, less than 1% unchanged); biliary/fecal (15-30%)
Category C
Category C
Antipsychotic
Antipsychotic